Parameta Logo
parameta logo
OTC Market Data

Navigating risk in the OTC space with enhanced market data

Jonathan Cooper
By Jonathan Cooper, Chief Revenue OfficerJun 24, 2024
Navigating risk in the OTC space with enhanced market data

SHARE


Navigating risk in the OTC space with enhanced market data

How can access to more reliable market data help participants in the OTC derivatives market navigate liquidity risks and identify market opportunities in an evolving sector?

Our exclusive survey of perspectives from leading participants in the OTC market has revealed a sector well-placed to lay the foundations for more effective operations in 2024 and beyond. There are high levels of confidence among market participants that they have the capabilities needed to carry the market forwards, and a general openness to embracing innovation. Given this, the stage is certainly set for smoother operations at an opportune moment for OTC derivatives, which are seen as a promising hedge against volatility.

Chapter three of our state-of-the-market report explores how access to reliable, in-depth data can be used to strike the right balance between risks and opportunities in an evolving market.

Navigating liquidity challenges

An increase in regulatory oversight and the establishment of central counterparties (CCPs) has put the OTC space on a more stable footing than previous years, which is an important milestone for establishing confidence in the sector’s growth potential – it is currently projected to reach $25.81 trillion by 2032. However, while growing regulation has helped lift market confidence, respondents are concerned by a subsequent decrease in liquidity in the market, driven in no small part by historically high interest rates.

Risks posed by this growth in liquidity challenges include rising price volatility, a lack of CCPs willing to engage in large trades, and greater difficulty entering and exiting market positions. Given the challenges present in the market, there is a greater need for more data to power the algorithms and models that can help participants more effectively manage risk and identify opportunities.

Many buy-side respondents worry that they are over-reliant on the sell-side for their information and would benefit from open and accountable third party data providers to get a better (and more objective) read on the market.

Supporting the AI transition

As the OTC markets evolve, there will be a greater need for access to data in order to support the market’s transition to AI-powered infrastructure. It’s an encouraging outcome of our survey that market participants broadly support this move to leverage AI and machine learning in order to improve processes and unlock profitability.

However, despite overall confidence within the market that there is enough data available, there are concerns among some the buy-side that there is not currently enough data to support this transition without incurring additional risk. When the focus shifts to areas of APAC such as Hong Kong, these concerns grow stronger, with significantly less confidence in the levels of data needed.

While the markets seem generally aligned on the potential for harnessing AI in order to deliver enhanced execution, it is important the buy-side is supported to overcome any barriers to fully realizing the benefits. With the OTC space at an inflection point for growth and change, there is a need for all parties to embrace a mindset of adaptability and to gain a fuller understanding of the risks – and opportunities – present in the market. Read the report for more insights.

This communication and all information contained in or attached to it (including, but not limited to market prices/levels and market commentary) (the “Information”) is for informational purposes only, is confidential, may be legally privileged and is the intellectual property of one of the companies of TP ICAP plc group (“TP ICAP”) or third parties. The Information is directed to Eligible Counterparties and Professional Customers only and is not intended for Retail Clients (as each term is defined by the rules of the Financial Conduct Authority or equivalent). The Information is not, and should not be construed as, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy. The Information is not to be relied upon and is not warranted, including, but not limited, as to completeness, timeliness or accuracy and is subject to change without notice. All representations and warranties are expressly disclaimed. Access to the Information by anyone other than the intended recipient is unauthorised and any disclosure, copying or redistribution is prohibited. The Information and any opinions expressed within it are not to be relied upon as authoritative, or taken in substitution for seeking your own advice or the exercise of your own commercial judgment. The Information has no regard to specific investment objectives and does not comprise investment advice. The Information is not, and should not be construed as, an offer or solicitation to bid, sell or buy any product, investment, security or any other financial instrument. TP ICAP does not promote any of the contents of the Information. TP ICAP does not make any representation or warranty, express or implied, as to the accuracy, completeness or correctness of the Information, which is subject to change without notice. TP ICAP does not accept any responsibility or liability for any direct or indirect loss or damage, howsoever caused, arising from or in connection with the Information. In no circumstances may the products referred to herein be used for any purpose that would cause it to become a benchmark for the purposes of (a) the Regulation (EU) 2016/1011, (b) the UK version of Regulation (EU) 2016/1011 as on shored via the European Union (Withdrawal) Act 2018 (the “UK Benchmarks Regulation”) (c) other applicable benchmark regulation and/or (d) the IOSCO Principles for Financial Benchmarks in each case together with the relevant technical standards, whether by the products referred to being referenced in a financial instrument, financial contract or investment fund or otherwise. (“Prohibited Use”). The terms of this disclaimer are governed by the laws of England and Wales. For further regulatory information and our terms of business, please seewww.tpicap.com. ©TPICAP 2024


SHARE

Request Follow Up
Speak to our team